ProfileGDS5678 / 1419762_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 27% 23% 27% 90% 32% 29% 26% 23% 57% 26% 25% 27% 26% 27% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6536627
GSM967853U87-EV human glioblastoma xenograft - Control 22.5432323
GSM967854U87-EV human glioblastoma xenograft - Control 32.6275627
GSM967855U87-EV human glioblastoma xenograft - Control 47.4859690
GSM967856U87-EV human glioblastoma xenograft - Control 52.6709332
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7273429
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6459826
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5283723
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4581357
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5818826
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5660925
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5978927
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6055226
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.607627